Barcelona, España
Se ha realizado un estudio clínico de la aplicación de ciclosporina en colirio al 2% durante dos años y medio, sobre 48 animales afectados de queratoconjuntivitis seca. Los resultados obtenidos se han visto ligados a diferentes factores como son: el valor inicial del test de Schirmer, el estado de la córnea y la etiología y evolución del proceso. En todo caso, su aplicación aumenta la producción de lágrimas de forma significativa y/o proporciona aumento del bienestar ocular por la disminución de la inflamación local, permitiendo eliminar o disminuir la administración concomitante de sustitutos de lágrimas. * We have performed a 2 years long clinical study on 2% cyclosporine collyre administration on 48 dogs suffering from keratoconjunctivitis sicca. Results are influenced by several factors, as Schirmer test initial values, corneal status, and the etiology and evolution of the disease. Anyway, 2% cyclosporine collyre administration significantly in creases tear secretion and/or benefits ocular status by reducing local inflamation, thus allowing to diminish or eliminate administration of tear substitutes.
We have performed a 2 years long clinical study on 2% cyclosporine collyre administration on 48 dogs suffering from keratoconjunctivitis sicca. Results are influenced by several factors, as Schirmer test initial values, corneal status, and the etiology and evolution of the disease. Anyway, 2% cyclosporine collyre administration significantly in creases tear secretion and/or benefits ocular status by reducing local inflamation, thus allowing to diminish or eliminate administration of tear substitutes.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados